Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Panbela Therapeutics stock

Own Panbela Therapeutics stock in just a few minutes.

Panbela Therapeutics Inc is a biotechnology business based in the US. Panbela Therapeutics shares (PBLA) are listed on the NASDAQ and all prices are listed in US Dollars. Panbela Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Panbela Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PBLA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Panbela Therapeutics share price

Use our graph to track the performance of PBLA stocks over time.

Panbela Therapeutics shares at a glance

Information last updated 2021-03-10.
52-week range$2.37 - $9.99
50-day moving average $5.11
200-day moving average $3.93
Wall St. target price$9.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.09

Buy Panbela Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Panbela Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Panbela Therapeutics financials

Gross profit TTM $0
Return on assets TTM -44.04%
Return on equity TTM -81.45%
Profit margin 0%
Book value $0.99
Market capitalisation $42.7 million

TTM: trailing 12 months

Shorting Panbela Therapeutics shares

There are currently 191,015 Panbela Therapeutics shares held short by investors – that's known as Panbela Therapeutics's "short interest". This figure is 38.3% up from 138,118 last month.

There are a few different ways that this level of interest in shorting Panbela Therapeutics shares can be evaluated.

Panbela Therapeutics's "short interest ratio" (SIR)

Panbela Therapeutics's "short interest ratio" (SIR) is the quantity of Panbela Therapeutics shares currently shorted divided by the average quantity of Panbela Therapeutics shares traded daily (recently around 389826.53061224). Panbela Therapeutics's SIR currently stands at 0.49. In other words for every 100,000 Panbela Therapeutics shares traded daily on the market, roughly 490 shares are currently held short.

However Panbela Therapeutics's short interest can also be evaluated against the total number of Panbela Therapeutics shares, or, against the total number of tradable Panbela Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Panbela Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Panbela Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0207% of the tradable shares (for every 100,000 tradable Panbela Therapeutics shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Panbela Therapeutics.

Find out more about how you can short Panbela Therapeutics stock.

Panbela Therapeutics share dividends

We're not expecting Panbela Therapeutics to pay a dividend over the next 12 months.

Have Panbela Therapeutics's shares ever split?

Panbela Therapeutics's shares were split on 7 December 2017.

Panbela Therapeutics share price volatility

Over the last 12 months, Panbela Therapeutics's shares have ranged in value from as little as $2.3701 up to $9.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Panbela Therapeutics's is 0.0341. This would suggest that Panbela Therapeutics's shares are less volatile than average (for this exchange).

Panbela Therapeutics overview

Panbela Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics Inc. in December 2020.

Frequently asked questions

What percentage of Panbela Therapeutics is owned by insiders or institutions?
Currently 19.14% of Panbela Therapeutics shares are held by insiders and 8.676% by institutions.
How many people work for Panbela Therapeutics?
Latest data suggests 4 work at Panbela Therapeutics.
When does the fiscal year end for Panbela Therapeutics?
Panbela Therapeutics's fiscal year ends in December.
Where is Panbela Therapeutics based?
Panbela Therapeutics's address is: 712 Vista Boulevard, Waconia, MN, United States, 55387
What is Panbela Therapeutics's ISIN number?
Panbela Therapeutics's international securities identification number is: US86664M2061

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site